Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03538431 · ClinicalTrials.gov registry record · Phase 4
Improving Driving in Young People With Autism Spectrum Disorders
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT03538431: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT03538431 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03538431, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
This study will examine the effects of treatment with the anti-anxiety medicine buspirone on driving performance (eye tracking) in individuals with high-functioning autism spectrum disorder (HF-ASD). The study consists of an Assessment Visit at Massachusetts General Hospital (MGH), as well as two Driving Simulation visits that will take place at Massachusetts Institute of Technology (MIT). Subjects will be given buspirone and asked to take the medication for the two days preceding the Driving Simulation Visit.
Interventions
- DRUG Buspirone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2018-10-31 |
| Est. Completion | 2019-12-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03538431
The ClinicalTrials.gov registry entry for NCT03538431 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Buspirone is the first listed.
NCT03538431 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03538431 about?
NCT03538431 is a clinical study titled "Improving Driving in Young People With Autism Spectrum Disorders". This study will examine the effects of treatment with the anti-anxiety medicine buspirone on driving performance (eye tracking) in individuals with high-functioning autism spectrum disorder (HF-ASD). The study consists of an Assessment Visit at Massachusetts General Hospital (MGH), as well as two D...
What is the current status of trial NCT03538431?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2018-10-31. Estimated completion is 2019-12-16.
What interventions are being tested in trial NCT03538431?
The interventions under investigation include: Buspirone (DRUG).
Who is sponsoring clinical trial NCT03538431?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.